Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075829 · ClinicalTrials.gov registry record · Phase 3
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Phase 3 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 3
- Development phase
- 710
- Enrollment target
NCT00075829 is a Phase 3 study that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 710 participants.
The verdict
NCT00075829, a Phase 3 study, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 710 participants
- Enrollment target
Study Summary
The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant. Study subjects will be biologically assigned to the appropriate arm depending on the availability of an HLA-matched sibling. There is a nested randomized phase III trial of observation versus maintenance therapy following the second autologous transplant for patients on the tandem autologous transplant arm.
Interventions
- DRUG Dexamethasone
- DRUG Thalidomide
- PROCEDURE One Autologous Transplant
- PROCEDURE Non-Myeloablative Allogeneic Transplant
- PROCEDURE Second Autologous Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 710 participants |
| Start Date | 2003-12 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00075829
The ClinicalTrials.gov registry entry for NCT00075829 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 710 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Dexamethasone is the first listed.
NCT00075829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00075829 about?
NCT00075829 is a clinical study titled "Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)". The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant. Study subjects will be biologically assigned to the appropriate arm depending...
What is the current status of trial NCT00075829?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 710 participants. The study started on 2003-12. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00075829?
The interventions under investigation include: Dexamethasone (DRUG), Thalidomide (DRUG), One Autologous Transplant (PROCEDURE), Non-Myeloablative Allogeneic Transplant (PROCEDURE), Second Autologous Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00075829?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.